Begin main content

Oncotype DX in Women and Men with ER-PR-Positive, HER2-Negative, Early Stage Breast Cancer with Lymph Node Micrometastasis: Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Last updated: June 29, 2016
Project Number: RA0855-000
Product Line: Rapid Response
Research Type: Other Diagnostics
Report Type: Reference List
Result type: Report

Question

  1. In the adjuvant treatment setting, what is the clinical effectiveness of Oncotype DX in women and men with ER-PR-positive, HER2-negative early stage breast cancer with one lymph node micrometastasis?
  2. In the adjuvant treatment setting, what is the cost-effectiveness of Oncotype DX in women and men with ER-PR-positive, HER2-negative early stage breast cancer with one lymph node micrometastasis?
  3. What are the evidence-based guidelines regarding the use of Oncotype DX in women and men with ER-PR-positive, HER2-negative early stage breast cancer with one lymph node micrometastasis?

Key Message

One evidence-based guideline was identified regarding the use of Oncotype DX in women and men with ER-PR-positive, HER2-negative early stage breast cancer with one lymph node micrometastasis.